Nearly 90,000 bottles of children’s liquid pain medication recalled

Nearly 90,000 bottles of a popular children’s pain reliever have been pulled from shelves following customer reports of contamination, federal health officials announced this week.

The Food and Drug Administration published a notice detailing the recall of Taro Pharmaceuticals’ Children’s Ibuprofen Oral Suspension, a berry-flavored liquid medication designed for children between 2 and 11 years old. According to the agency, customers reported finding “a gel-like mass and black particles” in the product, prompting the recall action earlier this month.

Despite the concerning reports, FDA regulators have classified this as a low-risk recall, noting that the probability of serious injury or adverse health effects is “remote.” The agency has not reported any illnesses or injuries connected to the contaminated medication.

The affected medication was manufactured in India by Strides Pharma Inc., a major global supplier of generic and over-the-counter medicines. Strides initiated the recall procedure, according to the FDA notice. The company produces pharmaceutical products for numerous healthcare companies operating in the United States and international markets.

As of Friday morning, neither Strides Pharma nor Taro Pharmaceuticals had responded to requests for comment on the recall or provided additional details about the nature of the contamination.

This recall comes at a particularly sensitive time for the children’s medication market. Over the past two years, parents across the country have periodically faced shortages of children’s pain relievers and fever reducers, particularly during peak respiratory illness seasons. Market analysts note that any disruption in supply, even from a single manufacturer, can have ripple effects across the pharmaceutical supply chain.

Children’s ibuprofen products like the one recalled are commonly used to reduce fever and alleviate pain from various childhood ailments, including teething, earaches, and minor injuries. The medication is classified as an NSAID (non-steroidal anti-inflammatory drug) and works by reducing hormones that cause inflammation and pain in the body.

The FDA has not specified which retail outlets carried the affected product or in which states the medication was distributed. Parents who have purchased Taro’s Children’s Ibuprofen Oral Suspension are advised to check the FDA recall notice for specific lot numbers and expiration dates of the affected products.

Health experts recommend that consumers who have purchased the recalled medication discontinue use immediately and return the product to the place of purchase for a refund. Alternatively, they should dispose of the medication properly and contact their healthcare provider if they have concerns about possible exposure.

This recall highlights ongoing challenges in pharmaceutical manufacturing quality control, particularly for medications produced overseas. The FDA has increased scrutiny of foreign manufacturing facilities in recent years, but monitoring the global supply chain remains complicated.

Pediatric medications undergo rigorous safety testing before approval, but contamination can occur during manufacturing, packaging, or distribution processes. The FDA conducts regular inspections of pharmaceutical manufacturing facilities and maintains surveillance programs to identify potential safety issues with medications already on the market.

Consumers who wish to report adverse events or quality problems with any medication can submit a report through the FDA’s MedWatch Adverse Event Reporting program online or by calling 1-800-FDA-1088.